Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arotinolol + amlodipine + clonidine
- Development stage
- Preclinical
- Lead developer
- Sumitomo Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of three antihypertensive medications with different mechanisms of action. Arotinolol is a beta-blocker with additional alpha-blocking properties, amlodipine is a calcium channel blocker, and clonidine is a centrally acting alpha-2 adrenergic agonist. This combination may be used for treatment of hypertension that is resistant to monotherapy.
02
Targets
ADRB2 (β2)ADRA2C (α2C)ADRA2A (α2A)LTCC (Voltage-gated calcium channel (L-type))ADRA2B (α2B)ADRA1A (α1A)ADRB1 (β1)
Beyond the preview
Go deeper on arotinolol + amlodipine + clonidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arotinolol + amlodipine + clonidine.